Acadian Asset Management LLC raised its stake in shares of Summit Therapeutics PLC (NASDAQ:SMMT) by 0.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,851 shares of the company’s stock after buying an additional 1 shares during the period. Acadian Asset Management LLC owned approximately 0.10% of Summit Therapeutics PLC worth $145,000 at the end of the most recent quarter.

Separately, Renaissance Technologies LLC acquired a new stake in Summit Therapeutics PLC during the first quarter valued at approximately $267,000. Institutional investors and hedge funds own 21.86% of the company’s stock.

Summit Therapeutics PLC (NASDAQ SMMT) traded up 2.15% during trading on Thursday, hitting $12.80. 1,211 shares of the company traded hands. The company’s 50-day moving average is $12.73 and its 200 day moving average is $11.89. The firm’s market cap is $158.48 million. Summit Therapeutics PLC has a 52-week low of $5.31 and a 52-week high of $19.75.

TRADEMARK VIOLATION NOTICE: “Acadian Asset Management LLC Acquires 1 Shares of Summit Therapeutics PLC (SMMT)” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/17/acadian-asset-management-llc-acquires-1-shares-of-summit-therapeutics-plc-smmt.html.

Several equities analysts recently issued reports on the stock. ValuEngine upgraded shares of Summit Therapeutics PLC from a “sell” rating to a “hold” rating in a research note on Tuesday, June 6th. Canaccord Genuity reiterated a “buy” rating and issued a $28.00 target price on shares of Summit Therapeutics PLC in a research note on Friday, June 16th. Oppenheimer Holdings, Inc. set a $24.00 target price on shares of Summit Therapeutics PLC and gave the company a “buy” rating in a research note on Thursday, June 22nd. Finally, Zacks Investment Research upgraded shares of Summit Therapeutics PLC from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Tuesday, July 4th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Summit Therapeutics PLC has an average rating of “Buy” and a consensus target price of $25.00.

Summit Therapeutics PLC Company Profile

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).

Institutional Ownership by Quarter for Summit Therapeutics PLC (NASDAQ:SMMT)

Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.